BASEL, Switzerland, March 31, 2025 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in China BV100 patents have now been granted in over 25 countries, including in US, Europe, UK and China BioVersys AG (SIX: